BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27237051)

  • 1. Inhibition of Rb Phosphorylation Leads to mTORC2-Mediated Activation of Akt.
    Zhang J; Xu K; Liu P; Geng Y; Wang B; Gan W; Guo J; Wu F; Chin YR; Berrios C; Lien EC; Toker A; DeCaprio JA; Sicinski P; Wei W
    Mol Cell; 2016 Jun; 62(6):929-942. PubMed ID: 27237051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors.
    Vora SR; Juric D; Kim N; Mino-Kenudson M; Huynh T; Costa C; Lockerman EL; Pollack SF; Liu M; Li X; Lehar J; Wiesmann M; Wartmann M; Chen Y; Cao ZA; Pinzon-Ortiz M; Kim S; Schlegel R; Huang A; Engelman JA
    Cancer Cell; 2014 Jul; 26(1):136-49. PubMed ID: 25002028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation.
    Yang G; Murashige DS; Humphrey SJ; James DE
    Cell Rep; 2015 Aug; 12(6):937-43. PubMed ID: 26235620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
    Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
    Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex.
    Liu P; Gan W; Chin YR; Ogura K; Guo J; Zhang J; Wang B; Blenis J; Cantley LC; Toker A; Su B; Wei W
    Cancer Discov; 2015 Nov; 5(11):1194-209. PubMed ID: 26293922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sin1 phosphorylation impairs mTORC2 complex integrity and inhibits downstream Akt signalling to suppress tumorigenesis.
    Liu P; Gan W; Inuzuka H; Lazorchak AS; Gao D; Arojo O; Liu D; Wan L; Zhai B; Yu Y; Yuan M; Kim BM; Shaik S; Menon S; Gygi SP; Lee TH; Asara JM; Manning BD; Blenis J; Su B; Wei W
    Nat Cell Biol; 2013 Nov; 15(11):1340-50. PubMed ID: 24161930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
    Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
    Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
    Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic activity of letrozole and sorafenib on breast cancer cells.
    Bonelli MA; Fumarola C; Alfieri RR; La Monica S; Cavazzoni A; Galetti M; Gatti R; Belletti S; Harris AL; Fox SB; Evans DB; Dowsett M; Martin LA; Bottini A; Generali D; Petronini PG
    Breast Cancer Res Treat; 2010 Nov; 124(1):79-88. PubMed ID: 20054642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoregulation of the mechanistic target of rapamycin (mTOR) complex 2 integrity is controlled by an ATP-dependent mechanism.
    Chen CH; Kiyan V; Zhylkibayev AA; Kazyken D; Bulgakova O; Page KE; Bersimbaev RI; Spooner E; Sarbassov DD
    J Biol Chem; 2013 Sep; 288(38):27019-27030. PubMed ID: 23928304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
    Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
    Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer.
    Yuan Y; Wen W; Yost SE; Xing Q; Yan J; Han ES; Mortimer J; Yim JH
    Sci Rep; 2019 May; 9(1):7509. PubMed ID: 31101835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors.
    Goel S; Wang Q; Watt AC; Tolaney SM; Dillon DA; Li W; Ramm S; Palmer AC; Yuzugullu H; Varadan V; Tuck D; Harris LN; Wong KK; Liu XS; Sicinski P; Winer EP; Krop IE; Zhao JJ
    Cancer Cell; 2016 Mar; 29(3):255-269. PubMed ID: 26977878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity.
    Liu P; Guo J; Gan W; Wei W
    Protein Cell; 2014 Mar; 5(3):171-7. PubMed ID: 24481632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydrophobic motif site-phosphorylated protein kinase CβII between mTORC2 and Akt regulates high glucose-induced mesangial cell hypertrophy.
    Das F; Ghosh-Choudhury N; Mariappan MM; Kasinath BS; Choudhury GG
    Am J Physiol Cell Physiol; 2016 Apr; 310(7):C583-96. PubMed ID: 26739493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.